-
HD2026 Milton Wexler Biennial Symposium Day 3
Latest News
-
HD2026 Milton Wexler Biennial Symposium Day 2
⏱️ 23 min read | Day 2 of #HD2026 brought us updates on the mechanics of somatic instability, new ways to track HD in people, AI tools to help drive research forward, and developments in our understanding of the HTT protein. Catch up right here.
-
Building a Better Mouse(trap): A New Model of Huntington’s Disease
New mouse model gives insights into Huntington's disease
-
Taking new targets to the bank: the DNA repair protein ‘ATM’ is overactive in Huntington's disease
HD causes the normally helpful protein "ATM" to get a little overzealous. Now we can look for drugs to settle it down
-
2015 Huntington's Disease Therapeutics Conference: Day 3
Day 3 of updates from the annual HD Therapeutics Conference in Palm Springs
-
2015 Huntington's Disease Therapeutics Conference: Day 2
Day 2 of updates from the annual HD Therapeutics Conference in Palm Springs
-
2015 Huntington's Disease Therapeutics Conference: Day 1
Day 1 of updates from the annual HD Therapeutics Conference in Palm Springs
-
Unlocking the Potential of Antibodies as a Therapy for Huntington’s Disease
Antibodies are known for their role in immunity, but researchers repurpose them in many ways. Can they be used in HD?
-
Drug Improves Huntington’s Symptoms in Mice – and Their Offspring
HD drug changes DNA folding across generations
-
mTORC1 tips the scales in Huntington’s disease mice
Weighing the scales on mTORC1: A possible new target for HD therapeutics?
-
Can this synthetic oil help feed the brain in Huntington's disease?
A new study shows a synthetic oil called triheptanoin changes how HD brains use energy. But will it help HD?
-
Positive results announced for re-worked tetrabenazine drug in Huntington's disease
Modified 'heavy hydrogen' form of tetrabenazine appears safe and effective for chorea in Huntington's disease
HDBuzz Trial Tracker
Sites for Phase 3 trial for votoplam, INVEST-HD, now open. Updates on recruitment and first dosing imminent.
Show 9 more Show less
REGEN4HD, Phase 1 stem cell implantation study commences
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
